The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

By P. Senter, E. Sievers. Nature Biotechnology, 2012

688 citations recorded by the source corpus.

Subfields: Oncology, Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/4eea05c97bf698e8c62f888eaaf364daa01ac605

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Paul Polakis

In Radiology, Nuclear Medicine and Imaging

1. Paul Polakis
2. S. Bhakta
3. S. Panowski
4. Jagath R Junutula
5. H. Raab

Citations in the corpus

• Site-specific antibody drug conjugates for cancer therapy (2013, background): “Brentuximab vedotin, developed by Seattle Genetics in partnership with Millennium/Takeda for the treatment of anaplastic large cell lymphoma and Hodgkin lymphoma, chemically couples an anti-CD30 chimeric antibody with the highly potent antimitotic agent, monomethyl auristatin E (MMAE) through a prot”